Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment

Tseng, Jeng-SenJeng-SenTsengHsu, Kuo-HsuanKuo-HsuanHsuZheng, Zhe-RongZhe-RongZhengYang, Tsung-YingTsung-YingYangChen, Kun-ChiehKun-ChiehChenHuang, Yen-HsiangYen-HsiangHuangKANG-YI SUSUNG-LIANG YUChang, Gee-ChenGee-ChenChang2021-03-112021-03-1120210030-2414https://scholars.lib.ntu.edu.tw/handle/123456789/551890The characteristics and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in advanced EGFR-mutant lung adenocarcinoma patients with primary tumor resection (PTR) is not yet clear.animationEpidermal growth factor receptor; Epidermal growth factor receptor-tyrosine kinase inhibitor; Local ablative therapy; Lung adenocarcinoma; Primary tumor resection[SDGs]SDG3bevacizumab; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; protein tyrosine kinase inhibitor; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; ablation therapy; adult; advanced cancer; aged; ArticPrimary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatmentjournal article10.1159/000509664328948452-s2.0-85091323522WOS:000605446700004https://api.elsevier.com/content/abstract/scopus_id/85091323522